DURECT Corporation - Common Stock (DRRX)
1.9100
+0.0300 (1.60%)
NASDAQ · Last Trade: Jul 30th, 8:59 PM EDT
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill · July 30, 2025
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.
Via Benzinga · July 29, 2025
Via Benzinga · July 29, 2025
Via Benzinga · May 16, 2025

DRRX stock results show that Durect beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024

Via Benzinga · May 21, 2024

Via Benzinga · May 21, 2024

DRRX stock results show that Durect missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 13, 2024

DRRX stock results show that Durect beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 27, 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via Benzinga · December 18, 2023

Via Benzinga · November 22, 2023

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via Benzinga · March 27, 2024

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via Benzinga · November 13, 2023